These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 33444586)
61. Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation. Rymer JA; Chiswell K; Young L; Chiu A; Liu L; Webb L; Carlisle M; Friedman D; Wang TY JAMA Netw Open; 2023 Jun; 6(6):e2317156. PubMed ID: 37285155 [TBL] [Abstract][Full Text] [Related]
62. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972 [TBL] [Abstract][Full Text] [Related]
63. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922 [TBL] [Abstract][Full Text] [Related]
64. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. Lucijanic M; Jurin I; Jurin H; Lucijanic T; Starcevic B; Skelin M; Glasnovic A; Catic J; Jurisic A; Hadzibegovic I Int J Cardiol; 2020 Feb; 301():90-95. PubMed ID: 31748190 [TBL] [Abstract][Full Text] [Related]
65. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Hernandez I; Zhang Y; Saba S Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318 [TBL] [Abstract][Full Text] [Related]
66. PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study. Kocabaş U; Ergin I; Yavuz V; Murat S; Özdemir I; Genç Ö; Altın C; Tüner H; Meriç BK; Çoner A; Yüce Eİ; Boyraz B; Aslan O; Dal A; Şen T; İbişoğlu E; Erdoğan A; Özgeyik M; Demir M; Bilgel ZG; Şengör BG; Urgun ÖD; Doğduş M; Tekin DDN; Çakal S; Çayırlı S; Güler A; Karabulut D; Dalgıç O; Uzman O; Murat B; Şahin Ş; Karabulut U; Kıvrak T; Coşgun MS; Özyurtlu F; Kaplan M; Özçalık E; Cardiovasc Drugs Ther; 2024 Jun; 38(3):581-599. PubMed ID: 36527566 [TBL] [Abstract][Full Text] [Related]
67. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T; N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374 [TBL] [Abstract][Full Text] [Related]
68. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. Li RJ; Caughey GE; Shakib S J Thromb Thrombolysis; 2022 Feb; 53(2):425-435. PubMed ID: 34302286 [TBL] [Abstract][Full Text] [Related]
69. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack. Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012 [TBL] [Abstract][Full Text] [Related]
70. Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment. Ting C; Rhoten M; Dempsey J; Nichols H; Fanikos J; Ruff CT Clin Appl Thromb Hemost; 2021; 27():1076029620987900. PubMed ID: 33517715 [TBL] [Abstract][Full Text] [Related]
71. Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications. Sanborn D; Sugrue A; Amin M; Mehta R; Farwati M; Deshmukh AJ; Sridhar H; Ahmed A; Asirvatham SJ; Ou NN; Noseworthy PA; Killu AM; Mulpuru SK; Madhavan M Am J Cardiol; 2022 Jan; 162():80-85. PubMed ID: 34756422 [TBL] [Abstract][Full Text] [Related]
72. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system. Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885 [TBL] [Abstract][Full Text] [Related]
73. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085 [TBL] [Abstract][Full Text] [Related]
74. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. Stankovic P; Georgiew R; Frommelt C; Hammel S; Wittlinger J; Hoch S; Obradovic D; Dagres N; Wilhelm T J Thromb Thrombolysis; 2019 Apr; 47(3):384-391. PubMed ID: 30729376 [TBL] [Abstract][Full Text] [Related]
75. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. Guimarães HP; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Paixão M; Hoffmann-Filho CR; Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Junior RA; Moisés VA; Mesas CE; Ardito RV; Kalil PSA; Paiva MSMO; Maldonado JGA; de Lima CEB; D'Oliveira Vieira R; Laranjeira L; Kojima F; Damiani L; Nakagawa RH; Dos Santos JRY; Sampaio BS; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Lopes RD; Pavanello R; Cavalcanti AB; Berwanger O; Am Heart J; 2021 Jan; 231():128-136. PubMed ID: 33045224 [TBL] [Abstract][Full Text] [Related]
76. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338 [TBL] [Abstract][Full Text] [Related]
77. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. Stacy ZA; Richter SK Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727 [TBL] [Abstract][Full Text] [Related]
78. Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. Stoll S; Macha K; Marsch A; Gerner ST; Siedler G; Fröhlich K; Volbers B; Strasser EF; Schwab S; Kallmünzer B J Neurol; 2020 Jul; 267(7):2007-2012. PubMed ID: 32206901 [TBL] [Abstract][Full Text] [Related]
79. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ; J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859 [TBL] [Abstract][Full Text] [Related]
80. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. Bonde AN; Martinussen T; Lee CJ; Lip GYH; Staerk L; Bang CN; Bhattacharya J; Gislason G; Torp-Pedersen C; Olesen JB; Hlatky MA Circ Cardiovasc Qual Outcomes; 2020 Apr; 13(4):e006058. PubMed ID: 32283966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]